Rangasami, Vignesh K., Samanta, Sumanta, Parihar, Vijay Singh, Asawa, Kenta, Zhu, Keying, Varghese, Oommen P., Teramura, Yuji, Nilsson, Bo, Hilborn, Jöns, Harris, Robert A. and Oommen, Oommen P. ORCID: https://orcid.org/0000-0003-2768-0133 2021. Harnessing hyaluronic acid-based nanoparticles for combination therapy: A novel approach for suppressing systemic inflammation and to promote antitumor macrophage polarization. Carbohydrate Polymers 254 , 117291. 10.1016/j.carbpol.2020.117291 |
Abstract
Anti-inflammatory drugs such as dexamethasone (DEX) are commonly administered to cancer patients along with anticancer drugs, however, the effect of DEX on human cancers is poorly understood. In this article, we have tailored self-assembled nanoparticles derived from hyaluronic acid (HA) wherein, anti-inflammatory DEX was used as a hydrophobic moiety for inducing amphiphilicity. The HA-DEX micelles were subsequently loaded with chemotherapeutic agent, doxorubicin (DOX) (HA-DEX-DOX) and was utilized to deliver drug cargo to human cancer cells expressing different levels of CD44 receptors. We found that DEX suppressed the cytotoxicity of DOX in HCT116, while it synergistically enhanced cytotoxicity in MCF-7 cells. When we tested DOX and HA-DEX-DOX in an ex-vivo human whole blood, we found activation of complement and the coagulation cascade in one group of donors. Encapsulation of DOX within the nanoparticle core eliminated such deleterious side-effects. The HA-DEX-DOX also polarized bone-marrow-derived anti-inflammatory M2 macrophages, to pro-inflammatory M1 phenotype with the upregulation of the cytokines TNF-α, iNOS and IL-1β.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Pharmacy |
Publisher: | Elsevier |
ISSN: | 0144-8617 |
Last Modified: | 29 Oct 2024 15:30 |
URI: | https://orca.cardiff.ac.uk/id/eprint/173007 |
Actions (repository staff only)
Edit Item |